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Abstract
Objective—Docetaxel causes cell death through induction of apoptosis; however, cell death
characteristics for docetaxel have not yet been fully elucidated. We examined the role of focal
adhesion kinase (FAK) cleavage in docetaxel-mediated apoptosis.
Methods—FAK degradation after treatment with docetaxel was determined in both taxane-
sensitive (HeyA8 and SKOV3) and taxane-resistant (HeyA8-MDRand SKOV3-TR) ovarian
cancer celllines by Westernblot analysis. Cell growth was determined with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. FAK-targeting small interfering
RNA (siRNA) was used to decrease FAK expression. Apoptosis and caspase activity were
determined using commercially available kits.
Results—SKOV3 and HeyA8 celllines were both sensitive to docetaxel (IC50 levels,1–6.2 nmol/
L), whereas the SKOV3-TR and HeyA8-MDR cells were resistant (IC50 ≥250 nmol/L for both).
Docetaxel induced high rates of apoptosis in SKOV3 and HeyA8 cells (84% and 66% apoptosis,
respectively) but minimal apoptosis (5–8%) in SKOV3-TR and HeyA8-MDR cells. Similarly,
FAK was cleaved in SKOV3 and HeyA8 cells in response to docetaxel treatment but unchanged in
the resistant cells. Caspase-3 and caspase-8 activity also increased significantly in docetaxel-
treated SKOV3 and HeyA8 cells but not in the taxane-resistant cells. DEVD-fmk (caspase-3
blocker) was able to block both FAK cleavage and apoptosis mediated by docetaxel in SKOV3
and HeyA8 cells. FAK siRNA transfection resulted in 70% to 90% decrease in FAK levels in all
cell lines within 72 hours. FAK silencing augmented docetaxel-mediated growth inhibition (5- to
8-fold increase) and apoptosis in both of the taxane-sensitive and taxane-resistant cell lines.
Conclusions—Docetaxel induces FAK cleavage, mediated through activation of caspase-3, in
taxane-sensitive ovarian cancer cells but not in taxane-resistant cells. The absence of FAK
degradation may contribute to cell survival in taxane-resistant cells. FAK silencing promotes the
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in vitro efficacy of docetaxel in both taxane-sensitive and taxane-resistant cell lines and may serve
as a novel therapeutic approach.
Ovarian cancer is the leading cause of death from a gynecologic malignancy (1). The high
mortality is mainly due to advanced stage at presentation in most patients. Despite the
standard therapy of surgical cytoreduction and systemic platinum and taxane combination,
most patients develop recurrent disease and eventually succumb to their disease (2).
Therefore, novel therapeutic approaches are urgently needed for ovarian carcinoma.
The taxanes docetaxel and paclitaxel have assumed an important role in both the primary
and salvage treatment of ovarian cancer (3). Taxanes promote both polymerization (tubulin
assembly in microtubules) and inhibit depolymerization of microtubules causing a mitotic
arrest (4). However, the molecular events leading to apoptosis by taxanes are not fully
understood. It has been shown that paclitaxel inhibits mitosis in metaphase by stabilizing
microtubule dynamics instead of altering microtubule polymer mass (5). In addition to a G2-
M arrest, paclitaxel-induced apoptosis can also be initiated in the S phase of the cell cycle
(6). Modulation of several apoptosis-related proteins, including p53, p21, Bcl-2, and Bax,
has been shown upon treatment with paclitaxel (7–10).
Extracellular matrix molecules regulate cell function by acting as both structural support and
signaling mediators (11). Focal adhesion kinase (FAK) is a multifunctional nonreceptor
protein tyrosine kinase that localizes to sites of attachment to the extracellular matrix and
participates in cell adhesion–induced signaling (12, 13). FAK phosphorylation at Tyr397, a
residue lying immediately NH2 terminal to the catalytic domain, is vital for its biochemical
and biological functions (12, 13). FAK plays a role in cell migration, invasion, and
proliferation (14–17). FAK also functions in the transmission of a cell adhesion–dependent
cell survival signal (18, 19). Recent evidence suggests that FAK is also protective against
apoptosis induced by a variety of agents (20–24). The antiapoptotic functions of FAK are
mediated, in part, via mitogen-activated protein kinase and protein kinase B/Akt activation
(25–27). FAK is proteolytically cleaved during induction of apoptosis, and caspases have
been suggested to be involved (21, 28). Sasaki et al. have shown that cisplatin-induced FAK
cleavage and processing is in part mediated by caspase-3 (29). However, the effect of
docetaxel on FAK and its potential relevance for cell survival are not known in ovarian
carcinoma.
We have previously shown that FAK overexpression in ovarian carcinoma is predictive of
poor clinical outcome, and FAK plays a functionally significant role in ovarian cancer
migration and invasion (30). In the present study, we examined the functional role of FAK




The human epithelial ovarian cancer cell lines SKOV3 and HeyA8 (31, 32) and the taxane-
resistant counterparts of these cell lines, SKOV3-TR (SKOV3 taxane resistant, a kind gift of
Dr. Michael Seiden, Department of Medicine, Massachusetts General Hospital, Boston, MA;
ref. 33) and HeyA8-MDR (a kind gift of Dr. Isaiah J. Fidler, Department of Cancer Biology,
M.D. Anderson Cancer Center, Houston, TX; ref. 34), were maintained in RPMI 1640
supplemented with 10% fetal bovine serum and 0.1% gentamicin sulfate (Gemini
Bioproducts, Calabasas, CA) in 5% CO2/95% air at 37°C. In vitro experiments were done
with 70% to 80% confluent cultures.
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Two small interfering RNA (siRNA) constructs were purchased from Qiagen (Germantown,
MD): a control sequence with no homology to any human mRNA (as determined by BLAST
search; target sequence 5′-AATTCTCCGAACGTGTCACGT-3′) and a sequence designed
to target FAK mRNA (target sequence 5′-AAC-CACCTGGGCCAGTATTAT-3′),
previously shown to down-regulate FAK (27). Lyophilized product was reconstituted in the
provided buffer [100 mmol/L potassium acetate, 30 mmol/L HEPES potassium hydroxide, 2
mmol/L magnesium acetate (pH 7.4)], heated to 90°C for 60 seconds, incubated at 37°C for
60 minutes, and stored at −20°C until used.
Transfection of small interfering RNA
Cells (5 × 105) were plated in 35-mm plates and allowed to adhere for 24 hours. On the day
of transfection, 15 μL of RNAiFect Transfection Reagent (Qiagen) was added to 100 nmol/L
siRNA (12 μL) in EC-R buffer (73 μL; Qiagen) to give a final volume of 100 μL, incubated
at room temperature for 15 minutes, and added to plates in serum-containing media for 16
hours. Cells were collected as lysates or subjected to the indicated experiment.
Western blot analysis
Cells were lysed in modified radioimmunoprecipitation assay buffer (50 mmol/L Tris, 150
mmol/L NaCl, 1% triton, 0.5% deoxycholate plus 25 μg/mL leupeptin, 10 μg/mL aprotinin,
2 mmol/L EDTA, and 1 mmol/L sodium orthovanadate; Sigma Chemical Co., St. Louis,
MO) as previously described (30). Cells were removed by scraping and centrifuged at
12,500 rpm for 30 minutes. The protein concentration of the supernatant was determined
using a bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL), and whole-cell
lysates were analyzed by 7.5% SDS-PAGE. Samples were transferred to nitrocellulose by
semidry transfer (Bio-Rad Laboratories, Hercules, CA), blocked with 5% nonfat milk, and
incubated with 0.25 μg/mL anti-FAK antibody (Biosource International, Camarillo, CA) for
1 hour at room temperature. Antibody was detected with 0.167 μg/mL horseradish
peroxidase–conjugated anti-mouse secondary antibody (The Jackson Laboratory, Bar
Harbor, ME) and developed with an enhanced chemiluminescence detection kit (Pierce).
Equal loading was confirmed by detection of β-actin. Densitometric analysis was done by
Scion Imaging software (Scion Corp., Frederick, MD).
For experiments regarding FAK processing, 1.5 × 106 cells were plated in a six-well plate
overnight. On the following day, the medium was replaced with serum-free medium
containing MITO+ (serum extender for serum-free conditions; BD Biosciences, San Jose,
CA). Docetaxel was added at IC50 concentrations for 48 to 72 hours. At the time of harvest,
both the detached and attached cells were removed and lysed with modified
radioimmunoprecipitation assay buffer, as described above. For experiments regarding the
role of caspase-3, DEVD-fmk (20 μmol/L; BD Biosciences/Clontech, Palo Alto, CA) was
added 1 hour before adding docetaxel.
Cytotoxicity assay
To determine the IC50 concentration of cytotoxic drugs under different conditions, 2 × 103
cells were seeded onto 96-well plates and incubated overnight at 37°C, after which either
control or FAK-targeting siRNA was added. The medium was exchanged after 48 hours
with increasing concentrations of docetaxel (obtained from Aventis Pharma, Bridgewater,
NJ) dissolved in ethanol (final concentration range, 0.1–10,000 nmol/L prepared in medium)
or cisplatin (purchased from LKT Laboratories, Inc., St. Paul, MN) dissolved in water. After
a 96-hour incubation, 50 μL of 0.15% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide was added to each well and incubated for 2 hours. The supernatant was removed,
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and cells were dissolved in 100 μL DMSO. The absorbance at 570 nm was recorded using a
FALCON microplate reader (Becton Dickinson Lab ware, Bedford, MA), and cell survival
expressed as a percent increase or decrease above control conditions, after subtracting blank
A 570 readings. The IC50 concentration was determined by finding the A 570 reading
midpoint between maximal and minimal readings and finding the chemotherapy
concentration that intersects the growth curve at that A 570 reading.
Terminal deoxynucleotidyl transferase–mediated nick end labeling assay
Terminal deoxynucleotidyl transferase – mediated nick end labeling–positive cells were
detected using Dead End Fluorometric terminal deoxynucleotidyl transferase–mediated nick
end labeling system (APO-DIRECT, BD Biosciences/PharMingen, San Diego, CA)
according to the manufacturer’s instructions. Briefly, ovarian cancer cells in culture were
treated with varying concentrations of docetaxel and harvested after 12, 24, 48, or 96 hours.
Cells were fixed with 4% paraformaldehyde solution for 25 minutes on ice. Intracellular
DNA fragments were then labeled by exposing cells to fluorescein-12-dUTP, treated with
propidium iodide and RNase A solution, and analyzed by flow cytometry (EPICS XL,
Beckman Coulter, Miami, FL). The percentages of apoptotic cells were averaged over three
consecutive experiments.
Caspase activity
Ovarian cancer cells (1 × 106) in culture (six-well plates) were treated with or without
docetaxel at the cell line specific IC50 or IC90 concentration for 24 hours. After washing
with PBS, cells were lysed in 50 μL of cell lysis buffer provided. Caspase-3, caspase-8, and
caspase-9 activities were measured with the appropriate apoptosis detection kit (BD
Biosciences/Clontech, Palo Alto, CA), using substrate DEVD-AFC for caspase-3, IETD-
AFC for caspase-8, and LEHD-AMC for caspase-9.
Reagents
Docetaxel was purchased from Sanofi-Aventis (Bridgewater, NJ). Cisplatin was purchased
from LKT Laboratories. Unless otherwise indicated, chemicals were purchased from Sigma-
Aldrich (St. Louis, MO).
Statistical analysis
Differences were analyzed using Student’s t test, and P < 0.05 was considered significant.
All experiments were done at least in triplicate. The Statistical Package for the Social
Sciences (SPSS, Inc., Chicago, IL) was used for all analyses.
Results
In vitro sensitivity of ovarian cancer cell lines to docetaxel
We first analyzed the effect of docetaxel on the growth of ovarian cancer cell lines by using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay at doses ranging
from 0.1 to 10,000 nmol/L. Growth of ovarian cancer cells was inhibited in a dose-
dependent manner (Fig. 1). The IC50 levels for the SKOV3 and HeyA8 cells were 6.2 and 1
nmol/L, respectively. The IC50 levels for SKOV3-TR and HeyA8-MDR were 225 and 450
nmol/L, respectively (Fig. 1). Therefore, the SKOV3-TR and HeyA8-MDR cell lines were
36- and 300-fold more resistant to docetaxel, respectively.
Caspase activity increases with docetaxel therapy
Caspase activity is known to play an important role in cisplatin-mediated apoptosis, with
caspase-8 and caspase-9 as initiators and caspase-3 and caspase-7 as executors (35). Thus,
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we assayed caspase-3, caspase-8, and caspase-9 by testing the conversion of the substrates
DEVD-AFC (caspase-3), IETD-AFC (caspase-8), and LEHD-AMC (caspase-9) into free
AFC (for caspase-3 and caspase-8) and AMC (for caspase-9) after treatment with docetaxel
using both IC50 and IC90 levels (Fig. 2). Cisplatin was used as a positive control. Caspase-3
activity increased in a dose-dependent manner in the SKOV3 (2.8-fold with IC50 and 5.4-
fold with IC90 levels of docetaxel) and HeyA8 (1.8-fold with IC50 and 2.5-fold with IC90
levels of docetaxel) cell lines. Caspase-8 activity increased by 2.8- to 3-fold in SKOV3 cells
and by 2.8- to 2.9-fold in HeyA8 cells. Caspase-9 activity increased by 1.35- to 1.64-fold in
SKOV3 and 1.5- to 1.6-fold in HeyA8 cells. In contrast, docetaxel treatment (using IC50 and
IC90 levels for sensitive cell lines) was not able to induce caspase activity in the resistant
cell lines SKOV3-TR and HeyA8-MDR.
Focal adhesion kinase is cleaved in response to docetaxel
It has been reported that FAK may be cleaved by caspase-3 (21, 29, 36). Based on our
observations regarding modulation of caspase levels by docetaxel in ovarian cancer cells, we
next examined whether FAK is cleaved after treatment with docetaxel and whether there are
differences in extent of FAK cleavage between the taxane-sensitive and taxane-resistant cell
lines. In SKOV3 cells, FAK was cleaved after 48 and 72 hours of exposure to docetaxel
(Fig. 3A). The 71-kDa fragments increased after treatment with docetaxel, whereas the 125-
kDa fragments decreased. Similar findings were observed with the HeyA8 cells (data not
shown). However, taxane-resistant SKOV3-TR and HeyA8-MDR cells did not show any
increase in FAK cleavage products after treatment with docetaxel (Fig. 3B). To test the
dependence of FAK cleavage on caspase-3, the effect of DEVD-fmk (caspase-3 inhibitor)
was examined. In the presence of DEVD-fmk, docetaxel-induced FAK cleavage was
blocked. These results suggest that docetaxel-mediated FAK cleavage occurs via caspase-3.
Focal adhesion kinase is down-regulated with focal adhesion kinase–specific small
interfering RNA
Next, we sought to examine whether FAK silencing using siRNA will sensitize ovarian
cancer cells to docetaxel. We first optimized the transfection conditions for these cells lines
by testing various ratios of rhodamine-conjugated nonsilencing siRNA to RNAifect Reagent
(μg/μL) and determined that a ratio of 1:6 was optimal and resulted in about 90%
transfection efficiency. Treatment with FAK siRNA, but not control (nonsilencing) siRNA,
resulted in a detectable decrease in FAK expression after 24 hours of treatment and maximal
suppression of 90% after 72 hours of transfection (Fig. 4A). Actin expression was
unaffected by either control or FAK siRNA treatment, indicating that nonspecific down-
regulation of protein expression did not occur.
Focal adhesion kinase down-regulation sensitizes ovarian cancer cells to docetaxel
The effect of FAK silencing using siRNA on in vitro sensitivity of human ovarian cancer
cells to docetaxel was determined. Ovarian cancer cells were exposed to FAK siRNA or a
nonsilencing siRNA for 48 hours before treatment with increasing concentrations of
docetaxel. The fold differences were calculated at the point where 50% cytotoxicity was
observed. Docetaxel cytotoxicity was almost 5-fold greater after FAK down-regulation in
SKOV3 and 8-fold greater in HeyA8 cells (Fig. 4B and C). Next, we examined the effects of
FAK silencing in the taxane-resistant SKOV3-TR and HeyA8-MDR cells. Similar findings
were observed with the resistant cell lines (4.8-fold increase in sensitivity in SKOV3-TR
and 5.5-fold increase in HeyA8-MDR cells; Fig. 4D and E). Control siRNA treatment did
not affect sensitivity of ovarian cancer cells to docetaxel.
We then examined caspase-3 activity in response to FAK silencing and docetaxel treatment.
Caspase-3 activity was enhanced by docetaxel after FAK down-regulation in the taxane-
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sensitive cell lines (Fig. 5A) but not in the resistant cell lines (Fig. 5B). Treatment with FAK
siRNA or control siRNA alone did not potentiate the activity of caspase-3 in either taxane-
sensitive or taxane-resistant cell lines (Fig. 5A and B). Caspase-3 activity was 6.1-fold
higher in the SKOV3 cells and 4.8-fold higher in the HeyA8 cells after treatment with FAK
siRNA in combination with docetaxel (both Ps < 0.001 compared with treatment with
vehicle alone). Caspase-3 activity was also enhanced by docetaxel after FAK down-
regulation in the resistant cell lines (Fig. 5B). Thus, down-regulation of FAK alone does not
increase caspase-3 activity, but FAK inhibition enhances the docetaxel-mediated induction
of caspase-3 activity.
Focal adhesion kinase silencing enhances docetaxel-induced apoptosis
We examined the effect of FAK suppression on docetaxel-mediated apoptosis. We first
characterized induction of apoptosis by docetaxel alone in the ovarian cancer cells using the
terminal deoxynucleotidyl transferase–mediated nick end labeling assay. Cells were treated
with either IC50 or IC90 levels of docetaxel for the taxane-sensitive cell lines and harvested
at time intervals ranging from 12 to 96 hours. The percentage of apoptosis in the control
cells remained low over time in all cell lines (Fig. 6). After docetaxel treatment for 96 hours,
the proportion of apoptotic cells increased to 84% in the SKOV3 cells (Fig. 6A) and 66% in
the HeyA8 cells (Fig. 6B). To determine whether docetaxel-induced apoptosis is indeed
caspase mediated, we used the caspase-3 inhibitor DEVD-fmk, which significantly reduced
the proportion of apoptotic cells (Fig. 6C) in response to docetaxel after 72 hours (72–7% in
SKOV3 and 56–6% in HeyA8 cells). The level of apoptosis remained low in the taxane-
resistant cell lines despite treatment with docetaxel and was not affected by DEVD-fmk
(Fig. 6D).
To test whether apoptosis might be affected by FAK silencing, we used the IC20 levels of
docetaxel. Ovarian cancer cells were treated with FAK siRNA for 48 hours, and then
docetaxel was added. At the IC20 levels of docetaxel, about 41% apoptosis was observed in
the SKOV3 cells and 42% in the HeyA8 cells (Fig. 7). However, in combination with FAK
siRNA, apoptosis increased to 83% in the SKOV3 cells and 84% in the HeyA8 cells (both
Ps < 0.01 when compared with docetaxel alone). Next, we examined the effects of FAK
silencing with or without docetaxel on apoptosis in the taxane-resistant cells. Although
neither agent alone induced much apoptosis, the combination resulted in a marked increase
in apoptosis in the SKOV3-TR and HeyA8-MDR cells (Fig. 7B). Control siRNA did not
enhance apoptosis in combination with docetaxel (Fig. 7A–B). These findings suggest that
FAK silencing in combination with docetaxel has at least an additive effect on induction of
apoptosis.
Discussion
The major findings from our study are that FAK becomes degraded in ovarian cancer cells
after docetaxel treatment, which does not occur in taxane-resistant cells. Furthermore, FAK
gene silencing promotes docetaxel-mediated apoptosis and growth inhibition. FAK
suppression improved the efficacy of docetaxel in both taxane-sensitive and taxane-resistant
cell lines. These findings suggest that FAK is a substrate for docetaxel via caspase-3, and its
inhibition potentiates docetaxel’s apoptotic effects on ovarian cancer cells. Docetaxel is
being increasingly used in clinical settings due to its greater potency compared with
paclitaxel (37, 38) and lower risk of neuropathy (39, 40). We and others have shown that for
adjuvant therapy of ovarian carcinoma, docetaxel is at least as effective as paclitaxel in
combination therapy with platinum but may have a better side effect profile (39, 40).
Although taxanes are known to inhibit depolymerization of microtubules (4) and modulate
some apoptosis-related genes, such as p53, p21, Bcl2, and Bax (8–10, 41), other molecular
and biological effects have not been well characterized.
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Cell adhesion to extracellular matrix substrates regulates many aspects of normal cell
physiology, including proliferation, migration, and cell survival (42, 43). FAK is a
nonreceptor protein tyrosine kinase that is a critical mediator of signaling events between
cells and their extracellular matrix (12, 13). FAK is tyrosine phosphorylated upon integrin
binding or downstream of ligand binding by growth factor receptors (25, 44). The major site
of phosphorylation of FAK is Tyr397, which is vital for the biochemical and biological
functions of FAK. FAK activation at focal adhesion sites leads to cytoskeletal
reorganization, cellular adhesion, and survival. FAK is overexpressed by many human
tumors including colon (45, 46), breast (45), thyroid (46), ovarian (30, 47), and head and
neck cancers (48), making FAK a rational target for therapeutic intervention. We have
previously shown that FAK overexpression is associated with poor outcome in patients with
ovarian carcinoma (30). Furthermore, FAK plays a functionally important role in ovarian
cancer migration and invasion (30). FAK overexpression has been reported to protect cells
from stressors, including UV irradiation, hydrogen peroxide exposure, and etoposide
treatment (23). Although the mechanisms underlying such protective roles are not fully
understood, they may involve activation of nuclear factor-κB and induction of inhibitor of
apoptosis proteins (23).
FAK’s role in protecting tumor cells from apoptosis has been addressed previously (29, 49).
Tamura et al. have shown that malignant astrocytoma/glioblastoma and breast cancer cells
are resistant to apoptosis in nonadherent suspension culture conditions through a mechanism
involving FAK/phosphatidylinositol 3-kinase/Akt signaling (50). Phosphatidylinositol 3-
kinase binds to the phosphorylated Y397 residue in FAK, and this association may promote
phosphatidylinositol 3-kinase activity (51). FAK’s role in promoting cancer cell survival is
likely affected by multiple cellular and molecular factors, including state of cell attachment,
Src activity, and PTEN activity. The isolation and propagation of transfected cancer cells
that overexpress FRNK, a protein that functions as a dominant negative by either inhibiting
localization or competing for binding partners, indicated that suppression of FAK activity
may not in and of itself induce apoptosis (52).
Because FAK has been shown to play a role in promoting cell survival, it is not surprising
that certain stimuli, such as UV irradiation or growth factor deprivation, can promote the
cleavage and degradation of FAK during the early stages of cell apoptosis (13). The
cleavage of FAK coincides with the loss of FAK from focal contacts, cell rounding, and
redistribution of FAK to apoptotic membrane protrusions (53). Based on its amino acid
sequence, FAK contains caspase-3 cleavage sites, which are conserved in many species,
including human, chicken, and frog FAK cDNA sequences (13, 54). The caspase cleavage
sites in FAK serve to separate the kinase domain from the COOH-terminal focal adhesion
targeting sequences and may accelerate the cell death process. Jones et al. have shown that
inhibition of FAK localization to focal adhesions by expression of the FAT domain resulted
in increased sensitivity to apoptosis-inducing agents (55). Caspases are activated during
chemotherapy-induced apoptosis in various cell types, including ovarian cancer cells (10,
29). Furthermore, caspase-3-mediated FAK cleavage has been previously shown with
platinum-based chemotherapy (20, 29, 36). These findings raised the possibility that
docetaxel-induced apoptosis may involve disruption of cell attachment by caspase-mediated
FAK degradation. Cytotoxic agents, such as S-(1, 2-dicholorovinyl)-L-cysteine and
cisplatin, have been shown to result in cleavage of FAK and other cytoskeletal proteins,
resulting in cell detachment and apoptosis (20, 56). In our experiments, there was a
differential effect of docetaxel on taxane-sensitive and taxane-resistant cells with regard to
caspase activation and FAK degradation, which occurred in the former but not in the latter.
FAK suppression alone by siRNA did not induce substantial apoptosis or inhibit
proliferation in monolayer culture. However, FAK down-regulation in the presence of
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docetaxel-potentiated apoptosis in both taxane-sensitive and taxane-resistant cells. These
results suggest that FAK is an important survival factor for ovarian cancer cells.
Because of the pivotal role of FAK in many processes associated with cancer progression,
the inhibition of its function may present significant therapeutic opportunities. Strategies
aimed at inhibition of critical protein-protein interactions or inhibition of the kinase activity
of FAK are being devised (57). However, the importance of FAK kinase activity versus
other aspects of FAK activity in cancer development and progression needs to be shown.
Small molecule inhibitors are also being developed that act as competitors for ATP binding
at the catalytic site. We and others are using siRNA approaches for down-regulating FAK,
which may hold promise for clinical use.
In summary, we have shown that FAK is degraded during docetaxel-induced, caspase-
mediated apoptosis. Furthermore, our results indicate that FAK down-regulation can
sensitize ovarian cancer cells to docetaxel chemotherapy. These results suggest that FAK
suppression in combination with docetaxel chemotherapy may be an attractive therapeutic
combination in ovarian carcinoma, particularly in patients with shown resistance to
conventional chemotherapy.
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Effect of docetaxel on ovarian cancer cell growth: (A) HeyA8 and HeyA8-MDR or (B)
SKOV3 or SKOV3-TR cells were plated in 96-well plates and subsequently incubated with
increasing concentrations of docetaxel for 96 hours, and cell viability was determined.
Points, mean of three independent experiments; bars, SE.
Halder et al. Page 12














Effect of docetaxel on caspase-3 (A), caspase-8 (B), and caspase-9 (C) activity. Ovarian
cancer cells were treated with docetaxel for 24 hours followed by fluorometric profiling of
caspase activity using a commercially available kit. Columns, means of three independent
experiments; bars, SE.
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Docetaxel treatment results in FAK cleavage. The taxane-sensitive (A) and taxane-resistant
(B) SKOV3 cells were cultured in the presence of docetaxel for 48 or 72 hours. Western blot
analysis for FAK in SKOV3 and SKOV3-TR cells in the presence or absence of the
caspase-3 inhibitor DEVD-fmk.
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Effect of FAK silencing on docetaxel-sensitivity in ovarian cancer cell lines. A, Western blot
analysis of SKOV3 whole-cell lysates probed with anti-FAK and anti-actin monoclonal
antibodies. Bottom, densitometry results. Control siRNA did not significantly affect FAK
expression compared with untreated cells whereas FAK-specific siRNA resulted in >90%
suppression of FAK expression by 72 hours. Effects of docetaxel on (B) SKOV3, (C)
HeyA8, (D) SKOV3-TR, and (E) HeyA8-MDR growth were tested alone or in combination
with FAK siRNA or control siRNA. Points, means of three independent experiments; bars,
SE.
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FAK gene silencing potentiates docetaxel-induced caspase-3 activity in (A) SKOV3 and
HeyA8 and (B) SKOV3-TR and HeyA8-MDR cells. Columns, means of three experiments;
bars, SE. *, P < 0.01; **, P < 0.001.
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Effects of docetaxel on (A) SKOV3 and SKOV3-TR or (B) HeyA8 and HeyA8-MDR
ovarian cancer cells. The percentage of apoptosis was determined by terminal
deoxynucleotidyl transferase – mediated nick end labeling. Cells were treated with or
without IC90 concentration of docetaxel for the taxane-sensitive cell lines. Points, means of
three different experiments; bars, SE. Effect of docetaxel with or without the caspase-3
inhibitor (DEVD-fmk) on (C) SKOV3 and SKOV3-TR and (D) HeyA8 and HeyA8-MDR
ovarian cancer cell apoptosis. Columns, means of three independents experiments; bars, SE.
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Docetaxel-mediated apoptosis with or without FAK siRNA in (A) SKOV3 and HeyA8 and
(B) SKOV3-TR and HeyA8-MDR ovarian cancer cells. Columns, means of three
independent experiments; bars, SE. Doc, docetaxel.
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